An international research team of scientists from Singapore’s Agency for Science, Technology and Research (A*STAR), the Icahn School of Medicine at Mount Sinai in New York and Germany’s Eye Clinic Sulzbach is using a type of stem cell in the eye to grow the pigmented layer of retina that’s essential for vision. The approach is showing promise in monkeys.
The findings suggest that these retinal pigment epithelium (RPE) stem cell-derived RPE, or hRPESC-RPE, may be a useful source for cell replacement therapies to treat RPE-related blindness caused by diseases such as macular degeneration, the researchers suggest. The results are published in the journal Stem Cell Reports.
RPE is a layer of tissue that supports the neurosensory retina and is critical for vision. An estimated 200 million people live with diseases associated with RPE dysfunction, including macular degeneration. Early attempts at RPE replacement used cells from the patient—an approach with limitations—scientists have been searching for treatment using different populations of stem cells.
In 2012, scientists identified a type of adult cell in the RPE that’s normally dormant but that can be activated to take on a stem-cell-like state with self-renewing ability. These cells have the potential to differentiate into RPE cells and could therefore be used for RPE replacement therapies, the A*STAR-led team figured.
In their study, the researchers took hRPESC-RPE from donated adult eyes and grew them into RPE monolayers. When transplanted into the eyes of monkeys on a polymer scaffold, the RPE patches stably integrated for at least three months.
The stem cell-derived RPE patches partially took over and were able to support normal light-sensing function, the team showed. What’s more, the method didn’t cause vision-blocking retinal scarring that has been seen with other experimental approaches.
Multiple types of stem cells, including human embryonic stem cells and human-induced pluripotent stem cells, have been proposed as alternative sources for retinal replacement. A team led by Mount Sinai previously used gene transfer to activate a type of retinal cells called Müller glial to adopt stem-cell-like characteristics. The team prompted the cells to divide into light-sensing rod photoreceptor cells in blind mice.
Researchers led by the National Institutes of Health’s National Eye Institute used five chemicals to turn skin cells directly into rod photoreceptors.
The A*STAR-led researchers believe their study demonstrates the potential of using hRPESC-RPE transplants as a treatment for macular degeneration. Further studies are needed to test the method in monkey models of eye disease to gauge the therapeutic effect, the researcher suggested.
If the cells succeed, they could serve as an unlimited resource for human RPE. Because the cells are harvested from human eyes, the researchers suggested establishing hRPESC-RPE donor banks to provide cells that match individual patients so there is no immune rejection.
by Angus Liu
Source: fiercebiotech.com
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
